Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada * Author to whom correspondence should be addressed. Diversity2021,13(12), 673;https://doi.org/10.3390/d13120673 Submission received: 18 August 2021/Revised: 11 October 2021/Accepted: 23 November 2021/Publish...
Antisense oligonucleotide therapy is a promising new area of drug development, and multiple drugs using this technology have received FDA approval in recent years [56]. This form of therapy uses oligonucleotides—often referred to as AONs or ASOs—to bind via Watson–Crick base pairing to a targe...